Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Rastilav, Bahleda"'
Autor:
Antonin Levy, Daphné Morel, Matthieu Texier, Roger Sun, Jerome Durand-Labrunie, Maria E Rodriguez-Ruiz, Severine Racadot, Stéphane Supiot, Nicolas Magné, Stacy Cyrille, Guillaume Louvel, Christophe Massard, Loic Verlingue, Fanny Bouquet, Alberto Bustillos, Lisa Bouarroudj, Clément Quevrin, Céline Clémenson, Michele Mondini, Lydia Meziani, Lambros Tselikas, Rastilav Bahleda, Antoine Hollebecque, Eric Deutsch
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-13 (2024)
Abstract Background Immuno-radiotherapy may improve outcomes for patients with advanced solid tumors, although optimized combination modalities remain unclear. Here, we report the colorectal (CRC) cohort analysis from the SABR-PDL1 trial that evaluat
Externí odkaz:
https://doaj.org/article/e2332711ee644fd79fb6e8ed2a5b6190
Autor:
Antoine Adenis, Antoine Italiano, Carine Bellera, Philippe Cassier, Alban Bessede, Rastilav Bahleda, Jean-Philippe Metges, Sophie Cousin, Jean-Philippe Guégan, Coralie Cantarel, Michèle Kind, Jean Palussiere, Lucile Vanhersecke
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/f524c441d8ee4cfa9cd4ec0434e68762
Autor:
Lauren Seknazi, Arthur Geraud, Vincent Goldschmidt, Capucine Baldini, Stéphane Champiat, Christophe Massard, Sophie Postel-Vinay, Aurelien Marabelle, Rastilav Bahleda, Antoine Hollebecque, Cristina Smolenschi, Anas Gazzah, Jean-Marie Michot, Patricia Martin-Romano, Aurore Vozy, Perrine Vuagnat, François-Xavier Danlos, Arnaud Bayle, Linda Mahjoubi, Barbara Pistilli, Yohann Loriot, Santiago Ponce-Aix, Kaissa Ouali
Publikováno v:
Cancer Research. 83:P2-13
Background: Breast cancer (BC) is the most frequent cancer and the second leading cause of cancer death for women. Although there is a need of new treatments to improve BC outcome, patients with BC are still under-represented in early phase trials, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf3c7ec9e4e98d11575b6815653da494
https://doi.org/10.1158/1538-7445.sabcs22-p2-13-02
https://doi.org/10.1158/1538-7445.sabcs22-p2-13-02
Autor:
Caroline Robert, Christine Mateus, Christophe Massard, Roger Sun, Eric Deutsch, Lydie Cassard, Rastilav Bahleda, Severine Roy, Emilie Routier, Nathalie Chaput-Gras, Caroline Caramella, Emilie Lanoy, Alicia Larive, Yun Gan Tao, Dominique Schwob, Nathalie Ibrahim, Rita Maria Khoury Abboud, J -C Soria
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background A synergy between radiotherapy and anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA-4) monoclonal antibody has been demonstrated preclinically. The Mel-Ipi-Rx phase 1 study aimed to determine the maximum tolerated dose (MTD) and
Externí odkaz:
https://doaj.org/article/62905cdd020c468e9c46587c81407cea
Autor:
Jean-Charles Soria, Charles Ferte, Christophe Massard, Roger Sun, Guillaume Louvel, Eric Deutsch, Benjamin Frey, Markus Hecht, Rainer Fietkau, Nora Sundahl, Florian Putz, Andrea Lancia, Angela Rouyar, Marina Milic, Alexandre Carré, Enzo Battistella, Emilie Alvarez Andres, Stéphane Niyoteka, Edouard Romano, Jérôme Durand-Labrunie, Sophie Bockel, Rastilav Bahleda, Charlotte Robert, Celine Boutros, Maria Vakalopoulou, Nikos Paragios, Piet Ost, Udo Gaipl
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Combining radiotherapy (RT) with immuno-oncology (IO) therapy (IORT) may enhance IO-induced antitumor response. Quantitative imaging biomarkers can be used to provide prognosis, predict tumor response in a non-invasive fashion and improve
Externí odkaz:
https://doaj.org/article/231cb0065627444ebd7c169e765aa1cb
Autor:
Patricia, Martin-Romano, Leo, Colmet-Daage, Daphne, Morel, Capucine, Baldini, Loic, Verlingue, Rastilav, Bahleda, Anas, Gazzah, Stephan, Champiat, Andree, Varga, Jean Marie, Michot, Maud, Ngo-Camus, Claudio, Nicotra, Aurelien, Marabelle, Jean Charles, Soria, Etienne, Rouleau, Ludovic, Lacroix, Antoine, Hollebecque, Christophe, Massard, Sophie, Postel-Vinay
Publikováno v:
European Journal of Cancer. 173:133-145
Although the role of epigenetic alterations in oncogenesis has been well studied, their prevalence in metastatic solid tumours is still poorly described. We therefore aimed at: (i) describing the presence of epigenetic gene alterations (EGA) - define
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8024c5c9089cc5c5e59f2323e9efe197
https://doi.org/10.1016/j.ejca.2022.06.014
https://doi.org/10.1016/j.ejca.2022.06.014
Autor:
Joonil Jung, Joon Sang Lee, Mark A. Dickson, Gary K. Schwartz, Axel Le Cesne, Andrea Varga, Rastilav Bahleda, Andrew J. Wagner, Edwin Choy, Maja J. de Jonge, Madelyn Light, Steve Rowley, Sandrine Macé, James Watters
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-7 (2016)
Pre-clinical studies have shown that TP53 mutations can account for acquired resistance to HDM2 antagonists. This study provides clinical evidence for the emergence of TP53mutations in circulating cell-free DNA, seen in 5 out of 20 de-differentiated
Externí odkaz:
https://doaj.org/article/260fdcaadef641d3801dbcc9cba2ac83
Autor:
Jean-Charles Soria, Valerie Meresse Naegelen, Steve Blotner, Eliezer Shochat, Jean J. L. Tessier, Ruediger Rueger, Zhi-Xin Xu, Ernesto Guarin, Emilie Routier, Federico Rojo, Françoise Kraeber-Bodéré, Saoirse Dolly, Rastilav Bahleda, Joan Albanell, Udai Banerji, Maria Martinez-Garcia
PDF file, 130K.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::006b8947be1db4b35cb0c1be9eb3d2ac
https://doi.org/10.1158/1078-0432.22451105.v1
https://doi.org/10.1158/1078-0432.22451105.v1
Autor:
Manuel Hidalgo, Alex A. Adjei, Michael J. Wick, Nagdeep Giri, Robert Millham, Joseph O'Connell, Diana Gernhardt, Anthony W. Tolcher, Rastilav Bahleda, Tao Wang, Wen Wee Ma, Jean-Charles Soria, Emiliano Calvo
Supplementary Figure Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bc7b28485d54daef1abfee78646300c
https://doi.org/10.1158/1078-0432.22458201.v1
https://doi.org/10.1158/1078-0432.22458201.v1
Autor:
Razelle Kurzrock, Jessica Vermeulen, Brenda Tromp, Helgi van de Velde, Rajesh Bandekar, Thomas A. Puchalski, Brett Hall, Manjula Reddy, Neil Steven, Jean-Pascal Machiels, Luc Dirix, Isabelle Ray-Coquard, Florence Joly, Sally Clive, Jose A. Lopez-Martin, Christian Ottensmeier, Jean-Luc van Laethem, Rastilav Bahleda, Steven J. Cohen, Elena Elez, Josep Tabernero, Eric Angevin
Purpose: This phase I/II study evaluated safety, efficacy, and pharmacokinetics of escalating, multiple doses of siltuximab, a chimeric anti-interleukin (IL)-6 monoclonal antibody derived from a new Chinese hamster ovary (CHO) cell line in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d127ffa15f80df2402432a2a034c043
https://doi.org/10.1158/1078-0432.c.6521741.v1
https://doi.org/10.1158/1078-0432.c.6521741.v1